Recombinant Human IKK beta Protein

重组人IKK beta蛋白

I kappa B kinase 2 | I kappa B kinase beta | I-kappa-B kinase 2 | I-kappa-B-kinase beta | IkBKB | IKK beta | IKK-B | IKK-beta | IKK2 | IKKB | IKKB_HUMAN | IMD15 | Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta | Inhibitor of nu

rp214439-10μg

10μg

无载体

≥80%(SDS-PAGE)

Acts as part of the IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Also phosphorylates NCOA3. Post-translational: Upon cytokine stimulation, phosphorylated on Ser-177 and Ser-181 by MEKK1 and/or MAP3K14/NIK; which enhances activity. Once activated, autophosphorylates on the C-terminal serine cluster; which decreases activity and prevents prolonged activation of the inflammatory response. Acetylation of Thr-180 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the I-kappa-B pathway. Ubiquitinated. Monoubiquitination involves TRIM21 that leads to inhibition of Tax-induced NF-kappa-B signaling. According to PubMed:19675099, 'Ser-163' does not serve as a monoubiquitination site. According to PubMed:16267042, ubiquitination on 'Ser-163' modulates phosphorylation on C-terminal serine residues. Monoubiquitination by TRIM21 is dirupted by Yersinia yopJ.

重组表达

33.7 kDa

N-His

33.1 & 35.9 kDa, under reducing conditions

E. coli Accession #: O14920 | E. coli

<1.0 EU/μg

人(Human)

470-755 aa

MHHHHHHNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQA​

No

Yes